• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does First Trimester Ultrasound Provide Information Beyond What Is Provided by cfDNA Testing?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Ramdaney et al. (Prenatal Diagnosis, 2022) evaluated the utility of first trimester ultrasound (US) between 10 and 14 weeks to identify fetal findings that would impact clinical management for women

METHODS:

  • Retrospective review of patient data
  • Population
    • Pregnancies with an abnormal ICD-10 codes from August 2016 to December 2018 and a first trimester US
    • ICD-10 diagnosis of maternal, fetal, or placental finding were then further reviewed 
  • Study design
    • Included patients that had genetic testing and management decision data
    • Clinical characteristics: Maternal age | Maternal BMI | Gestational age at time of US | Gravidity and parity | Race/ethnicity
  • Primary outcome
    • Fetal findings that would not be detected by cfDNA screening alone

RESULTS:

  • 20,594 first-trimester US | 6064 unique patients
    • First trimester US with fetal findings that impacted management and testing recommendations: 4.6%
    • Percentage of findings in patients with negative aneuploidy testing or those that declined testing: 88.1%
  • Most frequent fetal findings
    • Fetal demise: 35.3%
    • Increased NT/cystic hygroma: 24.1%
    • Multiple anomalies: 12.6%
  • Majority of patients with fetal findings were patients who were not advanced maternal age (AMA)
    • Not AMA: 61.5%
    • AMA: 38.5%
  • AMA patients were more likely to have fetal findings than non-AMA (P=0.017)
  • There was no significant difference in the frequency of specific anomalies between AMA and non-AMA
    • P=0.103

CONCLUSION:

  • First trimester US identified actionable clinical outcomes beyond the scope of cfDNA screening, such as structural anomalies and fetal demise
  • The authors state

FT US has multiple benefits in allowing patients and providers a better understanding of what risks may exist in the pregnancy and informing potential testing strategies.

We would argue that absence of ultrasound prior to cfDNA screening has the potential to increase both financial and time costs as a direct result of unexpected abnormalities or errors, as well as cause delays to needed discussions regarding pregnancy management

Learn More – Primary Sources:

First trimester ultrasound in the age of cell-free DNA screening: What are we missing?

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What is the Best Strategy for Fetal Aneuploidy Screening?
Can First Trimester TV Ultrasound Assessment of Previous Cesarean Scar Predict Placenta Accreta Spectrum?
Does Ultrasound Early in Pregnancy Improve Fetal Cardiac Visualization in the Setting of Obesity?
Practical info on evidence based medicine for your women's healthcare practice
cfDNA vs. Routine Screening – How Do They Compare?
Is There a Role for NIPS In Pregnancies With Increased NT?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site